The company plans to add 1700 beds by FY27 through the organic route
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
Application based on results from the TROPION-Breast01 Phase III trial
This acquisition enables MTD to open new, strategic markets
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The facility will manufacture tablets, capsules, and injections for the oncology segment
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Subscribe To Our Newsletter & Stay Updated